Published On: Wed, Oct 19th, 2016

Inogen Inc (NASDAQ:INGN) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Inogen Inc (NASDAQ:INGN).

Most recent broker ratings

08/05/2016 – Inogen Inc had its “strong buy” rating reiterated by analysts at Needham & Company. They now have a USD 64 price target on the stock.

08/05/2016 – Inogen Inc was downgraded to “hold” by analysts at Stifel Nicolaus.

07/13/2016 – Inogen Inc had its “overweight” rating reiterated by analysts at JP Morgan.

06/08/2016 – Inogen Inc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 60 price target on the stock.

03/24/2016 – Piper Jaffray began new coverage on Inogen Inc giving the company a “neutral” rating. They now have a USD 46 price target on the stock.

05/14/2015 – Inogen Inc was downgraded to “hold” by analysts at Zacks.

03/12/2014 – William Blair began new coverage on Inogen Inc giving the company a “outperform” rating.

The share price of Inogen Inc (NASDAQ:INGN) was up +2.48% during the last day of trading, with a day high of 57.90. 102438 shares were traded during the last session.

The stock’s 50 day moving average is 59.11 and its 200 day moving average is 52.39. The stock’s market capitalization is 1.16B. Inogen Inc has a 52-week low of 28.81 and a 52-week high of 61.87.

Inogen, Inc. is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds. Its Inogen One G2 and Inogen One G3 have approximately five and 4.5 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory patient market and serves as a backup to its Inogen One system for ambulatory patients. The Company sells its products to home medical equipment providers in the United States and in foreign countries.